+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors



Screening for cardiac dysfunction in anthracycline-exposed childhood cancer survivors



Clinical Cancer Research 20(24): 6314-6323



To examine the utility and reliability of obtaining early echocardiographic measurements of left ventricular (LV) remodeling as well as blood biomarkers of cardiac injury in asymptomatic childhood cancer survivors at risk for LV dysfunction and congestive heart failure due to past exposure to anthracycline chemotherapy. Using a cross-sectional design, anthracycline-exposed childhood cancer survivors with preserved ejection fraction (EF; ≥50%) were evaluated using early echocardiographic indices and blood biomarkers of LV dysfunction. Survivors treated with ≥300 mg/m(2) anthracyclines [high risk (HR): n = 100] were compared with those treated with <300 mg/m(2) anthracyclines [low risk (LR): n = 50] and matched healthy controls (HC: n = 50). All echocardiograms were interpreted by an institutional cardiologist and a study cardiologist blinded to risk status. Time from diagnosis was comparable for HR (12.0 years) and LR (13.2 years, P = 0.8) survivors. Echocardiograms: HR had lower LV thickness-dimension ratio (Z-score: HR: -0.62, LR: -0.03, HC: -0.02; P < 0.001), increased LV wall stress (HR: 66.7 g/cm(2), LR: 56.6 g/cm(2), HC: 54.2 g/cm(2); P < 0.01), and higher myocardial performance index (HR: 0.51, LR: 0.46, HC: 0.46; P < 0.01). Interobserver correlation (clinical/blinded reading) for all echocardiographic indices was excellent (range: R = 0.76-0.97, P < 0.001). Blood biomarkers: With the exception of NT-proBNP (r = 0.28, P < 0.01), there was no correlation between blood biomarkers (B-type natriuretic peptide, Troponin-T, ST-2, Galectin-3) and LV dysfunction. Childhood cancer survivors with preserved EF 10+ years from anthracycline exposure had dose-dependent changes in echocardiographic markers of LV dysfunction.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055671196

Download citation: RISBibTeXText

PMID: 24947931

DOI: 10.1158/1078-0432.CCR-13-3490


Related references

Screening for Anthracycline-Related Cardiac Dysfunction in Childhood Cancer Survivors: Can Less be More?. Pediatric Blood and Cancer 62(12): 2067-2068, 2016

Accuracy of a Novel Handheld Wireless Platform for Detection of Cardiac Dysfunction in Anthracycline-Exposed Survivors of Childhood Cancer. Clinical Cancer Research 24(13): 3119-3125, 2018

Treatment for asymptomatic anthracycline-induced cardiac dysfunction in childhood cancer survivors: the need for evidence. Journal of Clinical Oncology 21(17): 3377; Author Reply 3377-8, 2003

Speckle tracking echocardiography detects decreased cardiac longitudinal function in anthracycline-exposed survivors of childhood cancer. European Journal of Pediatrics 175(10): 1379-1386, 2017

Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: an analysis from the cardiac risk factors in childhood cancer survivors study. Pediatric Cardiology 34(4): 826-834, 2013

Screening and intervention for treatment-related cardiac dysfunction in childhood cancer survivors. Future Oncology 11(14): 2031-2034, 2016

Echocardiographic Detection of Cardiac Dysfunction in Childhood Cancer Survivors: How Long Is Screening Required?. Pediatric Blood and Cancer 62(12): 2197-2203, 2016

Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circulation. Cardiovascular Imaging 6(6): 873-880, 2014

Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy. Pediatric Blood and Cancer 62(1): 123-127, 2015

Lack of clinically significant cardiac dysfunction during intermediate dobutamine doses in long-term childhood cancer survivors exposed to anthracyclines. American Heart Journal 140(2): 315-323, 2000

Anthracycline-induced cardiac toxicity more likely in underweight childhood cancer survivors. Journal of Pediatric Hematology/Oncology 32(5): 411-415, 2010

Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. Journal of Clinical Oncology 25(24): 3635-3643, 2007

LV structure, LV function, and serum NT-proBNP in childhood cancer survivors without anthracycline or cardiac radiation exposures. Progress in Pediatric Cardiology 31(2): 141-142, 2011

Evaluation of traditional and novel measures of cardiac function to detect anthracycline-induced cardiotoxicity in survivors of childhood cancer. Journal of Cancer Survivorship 8(2): 183-189, 2015

Design and baseline characteristics for the ACE Inhibitor After Anthracycline (AAA) study of cardiac dysfunction in long-term pediatric cancer survivors. American Heart Journal 142(4): 577-585, 2001